Atlas Trials

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Clinical trial NCT02649686 · COMPLETED

Trial details

NCT number
NCT02649686
Sponsor
Canadian Cancer Trials Group
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2016-05-17
Primary completion
2017-09-25
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.